PR90324

WELLESLEY, Mass. and NEW YORK, June 29, 2021 /PRNewswire=KYODO JBN/--

-- The innovative RTSM leader grew over 100% in 2020, plans to accelerate

global expansion and support critical demand for products and services

4G Clinical, a cutting-edge randomization and trial supply management (RTSM)

company, announced it has entered into an agreement to receive a growth equity

investment of over $230MM from Goldman Sachs Asset Management ("Goldman

Sachs"). The investment will be used to fund 4G Clinical's continued global

expansion, support the growing demand for 4G's products, and to further the

company's mission of bringing crucial medicines to those who need them,

faster.  

Logo - https://mma.prnewswire.com/media/554411/4G_Clinical_Logo.jpg

Logo - https://mma.prnewswire.com/media/1552066/Goldman_Sachs_Logo.jpg

4G Clinical was founded in 2015 by seasoned entrepreneurs and RTSM technology

experts, David Kelleher and Ed Tourtellotte, to accelerate clinical trials by

leveraging Natural Language Processing (NLP) to disrupt the way trials are

executed. 4G Clinical's Prancer RTSM(R) enables life sciences companies to

reach First Patient In (FPI) up to 50% faster than other providers and

implement mid-study changes more efficiently. 4G Clinical's clinical supply

optimization solution, 4C Supply(R), incorporates real-time RTSM actuals to

prevent stock-outs and reduce drug waste. Life sciences organizations are also

increasingly shifting to modern eClinical solutions like 4G Clinical's Prancer

RTSM(R) and 4C Supply(R) to address the rising complexity of clinical trials.

To date, 4G Clinical supports clinical trials for over 100 biotech and pharma

clients globally.

"As life sciences companies strive for creativity and innovation in trial

designs, they cannot afford to be limited by technology," said Ed Tourtellotte,

CTO of 4G Clinical. "Our vision was to build Prancer RTSM(R) to handle any type

of trial within any indication. We've held to that vision, enabling our biotech

and pharma clients to let the science lead."

"This investment is transformational," said David Kelleher, CEO of 4G Clinical.

"In just over 5 years, 4G Clinical has grown from a start-up to a globally

recognized leader in RTSM, helping life sciences organizations execute clinical

trials of any size and complexity throughout the drug development lifecycle. To

maximize our impact on lives around the globe, we must unwaveringly drive

innovation in our technology and processes to tackle clinical trial

bottlenecks. This investment from Goldman Sachs ensures that we will not be

constrained in any way in that effort."

"The eClinical Solutions market has expanded rapidly over the past several

years with best-in-class, tech-first solutions leading the way, presenting an

exciting opportunity for Goldman Sachs," said Jason Kreuziger, a Managing

Director in Goldman Sachs Asset Management. "4G Clinical's established

reputation and global reach to date underscores their immense potential over

the next few years. We are honored to partner with and help 4G Clinical

accelerate their growth," added Antoine Munfa, a Managing Director in Goldman

Sachs Asset Management.

For more information about 4G Clinical, as well as its products and services,

please visit: https://www.4gclinical.co.jp/ja/home.

About 4G Clinical

4G Clinical is a global leader in randomization and trial supply management

(RTSM) and supply forecasting optimization software for the life sciences

industry, offering the only fully cloud-based, 100% configurable and flexible

solution utilizing natural language processing (NLP) to accelerate clinical

trials. 4G Clinical is headquartered in the Boston Biotech corridor of

Wellesley, MA, with offices in Europe and Asia. Learn more at

www.4gclinical.com.

About Goldman Sachs Asset Management

Bringing together traditional and alternative investments, Goldman Sachs Asset

Management provides clients around the world with a dedicated partnership and

focus on long-term performance. As the primary investing area within Goldman

Sachs (NYSE: GS), we deliver investment and advisory services for the world's

leading institutions, financial advisors and individuals, drawing from our

deeply connected global network and tailored expert insights, across every

region and market--overseeing more than $2 trillion in assets under supervision

worldwide as of March 31, 2021. Driven by a passion for our clients'

performance, we seek to build long-term relationships based on conviction,

sustainable outcomes, and shared success over time. Follow us on LinkedIn (

https://c212.net/c/link/?t=0&l=en&o=3210168-1&h=2048276807&u=https%3A%2F%2Fwww.linkedin.com%2Fshowcase%2Fgoldman-sachs-assetmanagement%2F&a=LinkedIn

).

For more information, please contact: 4gclinical@luminapr.com

SOURCE: 4G Clinical